Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM
is distinguished from monoclonal gammopathy of undetermined significance by a much …

Supportive care plays an increasingly important role in the modern management of multiple
myeloma. While modern treatments have significantly prolonged overall and progression …

Background Thalidomide plus dexamethasone (TD) is a standard induction therapy for
myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) …

Patients with multiple myeloma (MM) have an increased risk of venous thrombosis.
Interestingly, excess risk of venous thromboembolism has been observed among patients …

Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs
are at high risk of venous thromboembolism (VTE), but data are lacking from large …

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma
cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of …

Venous thromboembolism (VTE) remains a major cause of morbidity and mortality in
patients with cancer. Although some very well validated scores delineate the risk of VTE by …

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …

Monoclonal gammopathy of undetermined significance is one of the most common pre-
malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are …

No comprehensive evaluation has been made to assess the risk of viral and bacterial
infections among patients with monoclonal gammopathy of undetermined significance …